Wisconsin Pharmacal
This article was originally published in The Gray Sheet
Executive Summary
FDA approves premarket approval application supplement for production of the company's Reality female condoms at Chartex International's London, England plant. The company's original PMA, approved in May 1993, covered a limited-capacity facility in Jackson, Wisconsin ("The Gray Sheet" May 17, 1993, p. 6). With FDA approval of the large-capacity Chartex facility, Wisconsin Pharmacal will begin sales to approximately 5,000 public health clinics within 30 days. Retail marketing will start in July "with national distribution completed by fall," the firm says. The company has been selling the devices to a limited number of public health clinics since September 1993, and has "a current back order of four to six months"
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.